Nektar Therapeutics Expected to Earn Q3 2022 Earnings of ($0.54) Per Share (NASDAQ:NKTR)

Nektar Therapeutics (NASDAQ:NKTRGet Rating) – Analysts at Zacks Research issued their Q3 2022 earnings per share estimates for shares of Nektar Therapeutics in a research note issued to investors on Monday, September 19th. Zacks Research analyst K. Shah forecasts that the biopharmaceutical company will post earnings per share of ($0.54) for the quarter. The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($2.15) per share. Zacks Research also issued estimates for Nektar Therapeutics’ Q4 2022 earnings at ($0.22) EPS, FY2022 earnings at ($2.10) EPS, Q1 2023 earnings at ($0.24) EPS, Q2 2023 earnings at ($0.21) EPS, Q3 2023 earnings at ($0.24) EPS, Q4 2023 earnings at ($0.22) EPS, FY2023 earnings at ($0.92) EPS, Q1 2024 earnings at ($0.22) EPS, Q2 2024 earnings at ($0.23) EPS and FY2024 earnings at ($0.97) EPS.

Nektar Therapeutics (NASDAQ:NKTRGet Rating) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.85) EPS for the quarter, topping analysts’ consensus estimates of ($1.01) by $0.16. The firm had revenue of $21.59 million during the quarter, compared to analysts’ expectations of $22.75 million. Nektar Therapeutics had a negative return on equity of 82.40% and a negative net margin of 544.77%. The firm’s quarterly revenue was down 23.8% compared to the same quarter last year. During the same quarter last year, the business posted ($0.69) EPS.

A number of other analysts have also recently commented on the company. JPMorgan Chase & Co. cut Nektar Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Monday, August 8th. StockNews.com upgraded Nektar Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 11th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $13.17.

Nektar Therapeutics Trading Down 2.1 %

Nektar Therapeutics stock opened at $3.22 on Thursday. The stock has a market cap of $603.44 million, a PE ratio of -1.14 and a beta of 1.16. The stock has a 50-day moving average price of $4.11 and a 200 day moving average price of $4.45. Nektar Therapeutics has a 52 week low of $3.02 and a 52 week high of $19.37.

Insider Activity

In other news, insider Jonathan Zalevsky sold 10,560 shares of Nektar Therapeutics stock in a transaction dated Tuesday, August 16th. The stock was sold at an average price of $4.76, for a total value of $50,265.60. Following the transaction, the insider now directly owns 400,839 shares of the company’s stock, valued at approximately $1,907,993.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Jonathan Zalevsky sold 10,560 shares of Nektar Therapeutics stock in a transaction dated Tuesday, August 16th. The stock was sold at an average price of $4.76, for a total value of $50,265.60. Following the transaction, the insider now directly owns 400,839 shares of the company’s stock, valued at approximately $1,907,993.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Howard W. Robin sold 13,759 shares of the business’s stock in a transaction that occurred on Tuesday, August 16th. The stock was sold at an average price of $4.76, for a total value of $65,492.84. Following the transaction, the chief executive officer now directly owns 1,017,807 shares in the company, valued at $4,844,761.32. The disclosure for this sale can be found here. Insiders have sold 124,497 shares of company stock valued at $560,040 in the last three months. Corporate insiders own 3.38% of the company’s stock.

Hedge Funds Weigh In On Nektar Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Vantage Consulting Group Inc acquired a new position in shares of Nektar Therapeutics in the 2nd quarter valued at approximately $41,000. Nisa Investment Advisors LLC raised its position in shares of Nektar Therapeutics by 964.1% in the 2nd quarter. Nisa Investment Advisors LLC now owns 12,141 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 11,000 shares in the last quarter. Mackenzie Financial Corp acquired a new position in shares of Nektar Therapeutics in the 2nd quarter valued at approximately $47,000. Calton & Associates Inc. acquired a new position in shares of Nektar Therapeutics in the 1st quarter valued at approximately $55,000. Finally, Verition Fund Management LLC acquired a new position in shares of Nektar Therapeutics in the 1st quarter valued at approximately $55,000. 96.99% of the stock is owned by institutional investors and hedge funds.

About Nektar Therapeutics

(Get Rating)

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19.

Further Reading

Earnings History and Estimates for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.